CN101496894B - Medicament for treating fatty liver and preparation method thereof - Google Patents
Medicament for treating fatty liver and preparation method thereof Download PDFInfo
- Publication number
- CN101496894B CN101496894B CN2009100681774A CN200910068177A CN101496894B CN 101496894 B CN101496894 B CN 101496894B CN 2009100681774 A CN2009100681774 A CN 2009100681774A CN 200910068177 A CN200910068177 A CN 200910068177A CN 101496894 B CN101496894 B CN 101496894B
- Authority
- CN
- China
- Prior art keywords
- portions
- fatty liver
- radix
- medicine
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 28
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 28
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 28
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000006187 pill Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 7
- 235000012907 honey Nutrition 0.000 claims abstract description 6
- 210000000582 semen Anatomy 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 238000004137 mechanical activation Methods 0.000 claims description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 2
- 239000007963 capsule composition Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 241000522254 Cassia Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 7
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 244000201986 Cassia tora Species 0.000 abstract 1
- 235000014552 Cassia tora Nutrition 0.000 abstract 1
- 240000004307 Citrus medica Species 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 244000202052 Poncirus trifoliata Species 0.000 abstract 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000003908 liver function Effects 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 3
- 229950000628 silibinin Drugs 0.000 description 3
- 235000014899 silybin Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164439 Curcuma angustifolia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- -1 hexichol alkene Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a drug for treating fatty liver and a method for preparing the same, which belong to drug preparations containing undetermined structures from traditional herbal medicine. The drug is prepared from the following raw materials in portion by weight: 1 to 5 portions of prepared fleece flower root, 3 to 7 portions of tuckahoe, 3 to 7 portions of radix salviae miltiorrhizae, 3 to 7 portions of sicklesenna seed, 3 to 7 portions of hawthorn, 2 to 5 portions of rhizoma alismatis, 1 to 4 portions of lotus leaf, 2 to 5 portions of chicken-bone herb, 1 to 5 portions of fruit of trifoliate orange, 1 to 5 portions of radix curcumae, and 1 to 4 portions of citron, wherein the raw materials are ground into fin powder mechanically and then are prepared into honeyed pills with refined honey. The prepared drug has a total effective rate of 88.3 percent according to 60 nonalcoholic fatty liver sufferers in clinical application; besides, clinical observations show that the drug has definite curative effect, and a treatment group is obviously superior to a control group in the aspects of improving clinical symptoms and improving the curative effect observation of GGT.
Description
Technical field
The present invention relates to contain the pharmaceutical preparation of not confirming structure from traditional herbal medicines, specifically is a kind of medicine of treating fatty liver and preparation method thereof.
Background technology
Along with improving constantly of living standards of the people, the variation of dietary structure, and eat moving less life style more; Obesity, hyperlipemia, type 2 diabetes mellitus number are on the increase; The number of the infected of non-alcoholic fatty liver disease (NAFLD) is also day by day climbed to a higher point, and just progressively becomes the first hepatopathy of China, and wherein 1/3～1/2 is non-alcoholic stellato-hepatitis (NASH); The liver cirrhosis incidence rate is 15%～25% in the latter 10 years, wherein 30%～40% will die from hepatocarcinoma, liver failure and liver transplantation recurrence.In addition, fatty liver is also closely related with metabolism syndrome, type 2 diabetes mellitus and cardiovascular and cerebrovascular vessel incident.Therefore, NAFLD has become the new challenge in hepatopathy field, and it constitutes a serious threat to human health and social development.
Chinese patent 1215873C discloses a kind of " treatment fatty liver compound Chinese medicinal preparation and method for preparing "; It is processed by following components by weight portion, Fructus Crataegi 2-10 part, Radix Salviae Miltiorrhizae 1-5 part, Hirudo 0.5-3 part, Ganoderma 0.5-3 part, Radix Et Rhizoma Rhei 0.3-1.5 part, Radix Puerariae 0.3-1.5 part, Rhizoma Polygonati 0.3-1.5 part and Radix Bupleuri 0.2-1 part.Above-mentioned selected component is mixed by its ratio of weight and number; Decocte with water; Become thick paste with carry out concentrating under reduced pressure after the medical filtration that decocts gained, the mixing at every turn, again thick paste is carried out vacuum drying or spray drying, granulates, sieves, makes treatment fatty liver compound Chinese medicinal preparation after the drying again.This compound Chinese medicinal preparation is used for clinical total obvious effective rate can reach 72.58%, total effective rate 90.32%.
Summary of the invention
The present invention is exactly in order to solve the treatment problem of non-alcoholic fatty liver disease, and medicine of a kind of treatment fatty liver that can be good for liver, and lowering fat and preparation method thereof is provided.
Chinese medicine belongs to fatty liver " gathering " " hypochondriac pain " " expectorant is turbid " categories such as " feeling of fullness ", and the traditional Chinese medical science thinks that the primary disease cause is many owing to surfeit delicious food savoury, unscrupulous drinking, or experience the epidemic disease caused by damp-heat pathogen poison, or disorder of emotion etc.Its pathologic basis is expectorant, wet, the stasis of blood, long-pending, and diseased region is liver, and is closely related with the spleen kidney.Pathogenesis is a liver failing to maintain the normal flow of QI, dysfunction of the spleen in transportation, and retention of damp-heat in the interior, damp expectorant is turbid, blood stasis, knot blocks the liver venation and causes primary disease mutually.The present invention is just according to this theoretical prescription.Radix Polygoni Multiflori YIN nourishing nourishing the liver in the side, the Poria invigorating spleen to remove dampness, the Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, Semen Cassiae liver heat removing and eyesight improving pathogenic fire purging relieving constipation, the hawthorn digesting eliminate indigestion, Rhizoma Alismatis clearing away heat-damp and promoting diuresis diuretic, Fructus Aurantii, the sharp intestinal stasis relieving of Radix Curcumae soothing liver-QI amount to the liver soothing and the spleen invigorating, the effect of blood circulation promoting and blood stasis dispelling consumer product dredge stasis.
Modern pharmacology research proof, the Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling microcirculation improvement in the prescription of the present invention suppresses the collagen fiber hypertrophy, and Radix Salviae Miltiorrhizae active ingredient tool is removed oxygen-derived free radicals and lipoid peroxidization resistant; The contained equal hexichol alkene composition of Radix Polygoni Multiflori is to the fatty liver of rat and liver function infringement, and the rising of liver lipid peroxidation content has obvious antagonism, and Radix Polygoni Multiflori is rich in phospholipid and can stops cholesterol to be detained at serum at intrahepatic deposition and lipoid; Rhizoma Alismatis can be improved the liver fat metabolism, suppresses exogenous cholesterol absorption, suppresses the formation of TC in the liver; Semen Cassiae, Fructus Crataegi, Semen Cassiae all have the effect of treatment fatty liver, are used for the metabolic different links of fatty liver.Result of study shows that medicine of the present invention is the blood fat reducing level effectively, improves liver function, and losing weight effect alleviates the degree of fatty liver, and treating non-alcoholic fatty liver disease has definite curative effect.
The present invention realizes by following technical scheme.
A kind of medicine of treating fatty liver, it is to process by the raw material of following ratio of weight and number:
Radix Polygoni Multiflori Preparata 1-5 part Poria 3-7 part Radix Salviae Miltiorrhizae 3-7 part Semen Cassiae 3-7 part
Fructus Crataegi 3-7 part Rhizoma Alismatis 2-5 part Folium Nelumbinis 1-4 part Herba Abri 2-5 part
Fructus Aurantii 1-5 part Radix Curcumae 1-5 part Fructus Citri 1-4 part.
The medicine of said treatment fatty liver, it is to process by the raw material of following ratio of weight and number:
Radix Polygoni Multiflori Preparata 2-5 part Poria 4-6 part Radix Salviae Miltiorrhizae 4-6 part Semen Cassiae 4-6 part
Fructus Crataegi 4-6 part Rhizoma Alismatis 3-4 part Folium Nelumbinis 1-2.5 part Herba Abri 3-4 part
Fructus Aurantii 2-4 part Radix Curcumae 2-4 part Fructus Citri 1-2.5 part.
The medicine of said treatment fatty liver, it is to process by the raw material of following ratio of weight and number:
5.3 parts of 5.3 parts of Semen Cassiaes of 5.3 parts of Radix Salviae Miltiorrhizaes of 2.7 parts of Poria of Radix Polygoni Multiflori Preparata
3.5 parts of 1.8 parts of Herba Abris of 3.5 parts of Folium Nelumbinis of 5.3 portions of Rhizoma Alismatis of Fructus Crataegi
1.8 parts of 2.7 portions of Fructus Citris of 2.7 portions of Radix Curcumaes of Fructus Aurantii.
A kind of method for preparing of treating the medicine of fatty liver; Prepared slices of Chinese crude drugs Radix Polygoni Multiflori Preparata 1-5 part, Poria 3-7 part, Radix Salviae Miltiorrhizae 3-7 part, Semen Cassiae 3-7 part, Fructus Crataegi 3-7 part, Rhizoma Alismatis 2-5 part, Folium Nelumbinis 1-4 part, Herba Abri 2-5 part, Fructus Aurantii 1-5 part, Radix Curcumae 1-5 part, Fructus Citri 1-4 part of weighing by ratio of weight and the number of copies after will cleaning earlier; Mix homogeneously; Placed baking oven 60-70 ℃ of dry 12-18 hour, mechanical activation comminution is crossed the 60-80 mesh sieve after becoming fine powder;
Add refined honey 150-170g with every 100g fine powder again and process big honeyed pills, the heavy 9g of every ball, every ball is equivalent to primary crude drug 4.0g.
The present invention of preparation like this is through clinical practice non-alcoholic fatty liver disease patient 60 examples, total effective rate 88.3%; Clinical observation shows that the present invention has definite curative effect, is improving aspect the clinical symptoms and is improving that the treatment group obviously is superior to matched group in the observation of curative effect of GGT.
The specific embodiment
One. method for preparing
Take by weighing the prepared slices of Chinese crude drugs Radix Polygoni Multiflori Preparata 270g, Poria 530g, Radix Salviae Miltiorrhizae 530g, Semen Cassiae 530g, Fructus Crataegi 530g, Rhizoma Alismatis 350g, Folium Nelumbinis 180g, Herba Abri 350g, Fructus Aurantii 270g, Radix Curcumae 270g, the Fructus Citri 180g that clean; Mix homogeneously placed baking oven 60-70 ℃ drying 16 hours, and 80 orders sieved after mechanical activation comminution became fine powder; Every 100g fine powder adds refined honey 150-170g; Process big honeyed pills, every ball weighs 9 ± 0.5g, and every ball is equivalent to primary crude drug 4.0g.Can make honeyed pill 1000 balls according to theoretical recipe quantity.Refined honey system boils Mel 2-3 minute, and relative density is not less than 1.37, and temperature is at 116 ℃-118 ℃, the middle honey of Pressure gauge index between 0.2-0.4.
The method for preparing of the medicine of said treatment fatty liver, the prepared slices of Chinese crude drugs of weighing by above-mentioned ratio of weight and number are condensed into cream through extraction, and drying and granulating is processed tablet, or drop pill, or granule, or capsule formulation.
Two. indication and usage
Function cures mainly: the liver soothing and the spleen invigorating, blood circulation promoting and blood stasis dispelling, intestinal stasis relieving.Be applicable to fatty liver, alcoholic hepatitis, hyperlipemia and various chronic hepatitis and Glutamate pyruvate transaminase rises person.
Usage and dosage: oral every day three times, each 1-2 ball or follow the doctor's advice.
Points for attention: take the suitable low fat of these article, light diet avoids pungent food.
Untoward reaction: do not find untoward reaction.
Contraindication: the careful usefulness of chronic diarrhea loose stool person.
The every ball of specification: 9g/.
Storage: sealing storage, 9 months effect duration.
Three. clinical observation
Use the present invention and treat non-alcoholic fatty liver disease 60 examples, and contrast with silibinin capsule for treating non-alcoholic fatty liver disease 60 examples and to obtain clinical efficacy preferably.Report as follows:
1. data and method
1.1 case history is selected: case history all derives from my fatty liver out-patient of institute totally 120 examples, is divided into two groups at random, and 60 examples are organized in treatment, adopt medicine of the present invention; Matched group 60 examples adopt the silibinin capsule.Treatment group: male 41 examples, women 19 examples, age 20-60 year, mean age scope 42.7 ± 11.8 years old.Matched group: male 46 examples, women 14 examples, age 19-60 year, mean age scope 40.7 ± 12.4 years old.Two groups of age-sex's no significant differences (P＞0.05) have comparability.
1.2 diagnostic criteria: all observe " non-alcohol fatty liver practice guidelines " that the case history diagnosis all meets Chinese Medical Association's fatty liver and the formulation in 2006 of alcoholic liver disease group.Inclusion criteria: the color ultra fatty liver of clarifying a diagnosis; Stronger doctor is arranged from property person; Age is at 18-60 between year; Obtain informed consent.Exclusion standard: disease patients such as severe cardiac, brain, kidney; The diabetics of clarifying a diagnosis.
1.3 observation index: symptom (2) liver ultrasonoscopy (3) biochemical indicator glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST), glutamyl transpeptidase (GGT), triglyceride (TG), T-CHOL (CHO), low-density lipoprotein cholesterol (LDL) (4) Body Mass Index (BMI) before and after (1) treatment.Liver function, lipids detection (adopt the TBA-120FR automatic clinical chemistry analyzer, matched reagent is Japan and light, the color ultra PHILIPS-IU22 that is).
1.4 Therapeutic Method: be for 12 weeks two groups of courses of treatment.
Oral honeyed pill of the present invention is organized in treatment, 2 balls/inferior, and 3 times/day, oral, 4 weeks were a course of treatment, serve on for three courses of treatment.
4 of matched group oral silibinin capsules (Tianjin Tianlishi Group Co.,Ltd's production)/inferior, 3 times/day, oral, 12 weeks of the course of treatment.
During two groups of case treatments, formulate individuation dietary program and suitable exercise scheme, adjust dietary structure simultaneously; The control total amount of heat is taken in, and with high protein and low fat, enriches vitamin; An amount of carbohydrate diet is a principle, and controlling body weight is not used medicines such as other protect the liver, blood fat reducing during the treatment.
1.5 observation of curative effect:
(1) criterion of therapeutical effect: according to the 1st volume of .1993:76 of " new Chinese medicine clinical research guideline " Ministry of Health of the People's Republic of China.
(2) evaluation criteria:
Clinical cure: symptom and sign disappear basically, and color ultra inspection recovers normal, liver function (ALT, AST, GGT), and blood fat: cholesterol (CHO), glyceride (TG), low-density lipoprotein cholesterol (LDL) are reduced to normal range.
Effectively: symptom and sign take a turn for the better, and the color ultra Radiologic imaging of showing takes a turn for the better, make moderate progress decline >=30% or return to normal level of relevant indexs such as liver function, blood fat.
Invalid: as not reach above-mentioned standard.
1.6 statistical procedures: carry out statistical procedures with the SPSS14.0 statistical software.Measurement data is with (x ± s) expression, table two, table three employing t check; Table one, four adopts Ridit to analyze; Table five adopts X 2 test, and (correction of continuity is adopted in 1≤T≤5 o'clock; Accurate probability inspection method is adopted in T＜1 o'clock).
2. therapeutic outcome:
2.1 two groups of case comprehensive therapeutic effects relatively: treatment group patient cures 15 examples, 40 examples, invalid 5 routine total effective rates 91.7% take a turn for the better.Matched group is respectively 12 examples, 41 examples, 7 examples, total effective rate 88.3%.Two groups of total effective rates compare (P＞0.05), no significant difference.(seeing table 1)
Table 1 liang group treatment back total effective rate relatively
Compare P＞0.05 with the matched group total effective rate
2.2 liver function, change of blood sugar compare (seeing table 2) before and after two groups of treatments
Liver function and blood glucose (GLu) change relatively (x ± s) before and after the treatment of table 2 liang group
With preceding relatively * P＜0.05 of this group treatment, compare △ P＞0.05, △ △ P＜0.01 after * * P＜0.01 and the treatment of control group
2.3 blood fat, BMI change relatively (seeing table 3) before and after two groups of treatments
Blood fat BMI variation comparison before and after the table 3 liang group patient treatment (x ± s)
With preceding relatively * P＜0.05 of this group treatment, compare △ P＞0.05 after * * P＜0.01 and the treatment of control group
2.4 the color result's (seeing table 4) that changes before and after two groups of treatments
Color ultrasonogram changes (n) before and after the table 4 liang group treatment
Compare P＞0.05 (u=-0.23) with matched group
Above result shows that treatment group and matched group have definite curative effect to the treatment of non-alcoholic fatty liver disease; ALT, AST in improving liver function; Blood fat CHO, TG, LDL aspect; Reduce fasting glucose Glu, Body Mass Index BMI aspect, and do not have significant difference (P＞0.05) aspect the variation of liver iconography improving.And the treatment group obviously is superior to matched group (P＜0.01) in improving the observation of curative effect of GGT.
2.5 the doing well,improving situation compares (seeing table 5) before and after two groups of treatments
Doing well,improving situation (n) before and after the table 5 liang group treatment
Two groups of symptoms with the improvement rate as relatively, with △ P＜0.05 relatively after the treatment of control group, △ △ P＜0.01, △ △ △ P＞0.05
Treatment group doing well,improving rate: weak 87.1% (27/31), uncomfortable liver area 96.4% (27/28), anorexia 100% (9/9), abdominal distention 88.9% (24/27), constipation 100% (12/12), loose stool 77.8% (7/9), uncomfortable in chest 100% (18/18); Matched group doing well,improving rate: weak 33.3% (7/21), uncomfortable liver area 63.0% (17/27), anorexia 54.5% (6/11), abdominal distention 55% (11/20), constipation 37.5% (3/8), loose stool 50% (3/6), uncomfortable in chest 55.6% (5/9); Two groups of doing well,improving situation comparative statistics have notable difference (P＜0.01 or P＜0.05), and curative effect obviously is superior to matched group aspect the clinical symptoms improving in the present invention.
Claims (5)
1. medicine of treating fatty liver, it is to process by the raw material of following ratio of weight and number:
Radix Polygoni Multiflori Preparata 1-5 part Poria 3-7 part Radix Salviae Miltiorrhizae 3-7 part Semen Cassiae 3-7 part
Fructus Crataegi 3-7 part Rhizoma Alismatis 2-5 part Folium Nelumbinis 1-4 part Herba Abri 2-5 part
Fructus Aurantii 1-5 part Radix Curcumae 1-5 part Fructus Citri 1-4 part.
2. according to the medicine of the said treatment fatty liver of claim 1, it is characterized in that this medicine is to process by the raw material of following ratio of weight and number:
Radix Polygoni Multiflori Preparata 2-5 part Poria 4-6 part Radix Salviae Miltiorrhizae 4-6 part Semen Cassiae 4-6 part
Fructus Crataegi 4-6 part Rhizoma Alismatis 3-4 part Folium Nelumbinis 1-2.5 part Herba Abri 3-4 part
Fructus Aurantii 2-4 part Radix Curcumae 2-4 part Fructus Citri 1-2.5 part.
3. according to the medicine of the said treatment fatty liver of claim 1, it is characterized in that this medicine is to process by the raw material of following ratio of weight and number:
5.3 parts of 5.3 parts of Semen Cassiaes of 5.3 parts of Radix Salviae Miltiorrhizaes of 2.7 parts of Poria of Radix Polygoni Multiflori Preparata
3.5 parts of 1.8 parts of Herba Abris of 3.5 parts of Folium Nelumbinis of 5.3 portions of Rhizoma Alismatis of Fructus Crataegi
1.8 parts of Fructus Aurantii 2-4 part Radix Curcumae 2-4 part Fructus Citris.
4. the method for preparing of the medicine of the said treatment fatty liver of claim 1 is characterized in that:
A. prepared slices of Chinese crude drugs Radix Polygoni Multiflori Preparata 1-5 part, Poria 3-7 part, Radix Salviae Miltiorrhizae 3-7 part, Semen Cassiae 3-7 part, Fructus Crataegi 3-7 part, Rhizoma Alismatis 2-5 part, Folium Nelumbinis 1-4 part, Herba Abri 2-5 part, Fructus Aurantii 1-5 part, Radix Curcumae 1-5 part, Fructus Citri 1-4 part of weighing by ratio of weight and the number of copies after will cleaning; Mix homogeneously; Placed baking oven 60-70 ℃ of dry 12-18 hour, mechanical activation comminution is crossed the 60-80 mesh sieve after becoming fine powder;
B. every 100g fine powder adds refined honey 150-170g and processes big honeyed pills, the heavy 9g of every ball, and every ball is equivalent to primary crude drug 4.0g.
5. according to the method for preparing of the medicine of the said treatment fatty liver of claim 1, it is characterized in that: the prepared slices of Chinese crude drugs of weighing by ratio of weight and the number of copies are condensed into cream through extraction, and drying and granulating is processed tablet, or drop pill, or granule, or capsule formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100681774A CN101496894B (en) | 2009-03-19 | 2009-03-19 | Medicament for treating fatty liver and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100681774A CN101496894B (en) | 2009-03-19 | 2009-03-19 | Medicament for treating fatty liver and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101496894A CN101496894A (en) | 2009-08-05 |
| CN101496894B true CN101496894B (en) | 2012-05-02 |
Family
ID=40944303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100681774A Expired - Fee Related CN101496894B (en) | 2009-03-19 | 2009-03-19 | Medicament for treating fatty liver and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101496894B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641469B (en) * | 2011-02-22 | 2014-07-02 | 北京中医药大学东方医院 | Medicinal composition for preventing or treating nonalcoholic steatohepatitis |
| CN103007081B (en) * | 2012-11-27 | 2013-12-04 | 鞠法红 | Traditional Chinese medicine composition for curing non-alcoholic fatty liver disease |
| CN103736036A (en) * | 2014-01-28 | 2014-04-23 | 张怀胜 | Drug for treating nonalcoholic fatty liver disease and preparation method thereof |
| CN105079676A (en) * | 2015-09-18 | 2015-11-25 | 宋克垣 | Medicine for treating fatty liver and preparing method of medicine |
| CN106109767A (en) * | 2016-07-13 | 2016-11-16 | 郑亮 | A kind of compound preparation preventing and treating non-alcohol fatty liver |
| CN110123985A (en) * | 2019-05-06 | 2019-08-16 | 万勇 | A kind of lotus leaf blood-fat-lowering granule agent for treating fatty liver |
-
2009
- 2009-03-19 CN CN2009100681774A patent/CN101496894B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101496894A (en) | 2009-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101496894B (en) | Medicament for treating fatty liver and preparation method thereof | |
| CN1475229A (en) | Antifatigue compound Chinese medicine prescription and its preparation method | |
| CN101837087B (en) | Chinese medicinal composition for improving immunity, resisting fatigue and improving sexual function | |
| CN102258710A (en) | Traditional Chinese medicine composition for treating type II diabetes | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN102178733B (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| CN101919986B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN102949481A (en) | Health care tea for reducing blood pressure and blood lipid | |
| CN108042766A (en) | A kind of Bushen Tongluo supports brain cream and preparation method thereof | |
| CN104491798A (en) | Traditional Chinese medicine preparation for treating intestinal parasites and preparation process thereof | |
| CN104491797A (en) | Use of traditional Chinese medicine preparation in preparation of drug for treating intestinal parasites | |
| CN104383204A (en) | Herba elsholtziae-containing traditional Chinese medicine composition for lowering lipid | |
| CN102641469A (en) | Medicinal composition for preventing or treating nonalcoholic steatohepatitis | |
| CN102008598A (en) | Blood fat-lowering and liver-protecting composite as well as preparation prepared thereby and preparation method of preparation | |
| CN104840871A (en) | Traditional Chinese medicine for treating alcoholic liver injury | |
| CN100488546C (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN104524167A (en) | Traditional Chinese medicine preparation for treating liver cirrhosis and liver ascites and preparation method of traditional Chinese medicine preparation | |
| CN101695562B (en) | Chinese medicinal composition for treating viral hepatitis and preparation method thereof | |
| CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
| CN103405574B (en) | Medicinal composition for treating hypertension | |
| CN103860877B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN105343675A (en) | Traditional Chinese medicine preparation for treating adiposis and preparation method thereof | |
| CN101181463B (en) | Chinese medicine composition for treating diabetes and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120502 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |